[Drug therapy of urinary incontinence].
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D001418:Baclofen / Q000627:therapeutic use; D001561:Benzilates / Q000627:therapeutic use; D005039:Etilefrine / Q000627:therapeutic use; D006801:Humans; D010276:Parasympatholytics / Q000627:therapeutic use; D010643:Phenoxybenzamine / Q000627:therapeutic use; D013566:Sympathomimetics / Q000627:therapeutic use; D014326:Tropanes / Q000627:therapeutic use; D001743:Urinary Bladder / Q000294:innervation; D014549:Urinary Incontinence / Q000188:drug therapy*; D014550:Urinary Incontinence, Stress / Q000188:drug therapy
D000317:Adrenergic alpha-Antagonists; D001561:Benzilates; D010276:Parasympatholytics; D013566:Sympathomimetics; D014326:Tropanes; D010643:Phenoxybenzamine; D001418:Baclofen; C005860:tropenziline bromide; D005039:Etilefrine
Medikamentöse Therapie der Harninkontinenz.